^
    Back
    Association details:
    Biomarker:PRSS3 underexpression
    Cancer:Glioma
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Sci Adv
    Title:

    PRSS contributes to cetuximab resistance in colorectal cancer

    Published date:
    01/01/2020
    Excerpt:
    We also divided the patients with glioma who received bevacizumab monotherapy (n = 77) into two groups...the patients with glioma and low PRSS3 expression had longer PFS than the patients with high PRSS3 expression (median survival, 323 days versus 228 days, respectively; P = 0.0112; fig. S8, C and D).
    DOI:
    10.1126/sciadv.aax5576